Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioDelivery Sciences Planning Two Emezine PK Studies To Satisfy FDA Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

The company believes that the studies of the anti-emetic will take six to nine months to complete.

You may also be interested in...



BioDelivery Sciences' Prochlorperazine Oral Buccal Tablet Is Bucked Off Course

FDA "not approvable" letter for Emezine is due to the pharmacokinetic profile of its oral buccal tablet formulation.

Future BIO Global Efforts Include International Relations, Greenwood Says

HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13

Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio

Merger will create the leading generic injectable pharmaceutical company in the world.

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel